Comparative Pharmacology
Head-to-head clinical analysis: ETHINYL ESTRADIOL AND LEVONORGESTREL versus PREMPRO PREMPHASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHINYL ESTRADIOL AND LEVONORGESTREL versus PREMPRO PREMPHASE.
ETHINYL ESTRADIOL AND LEVONORGESTREL vs PREMPRO/PREMPHASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive; ethinyl estradiol provides estrogenic activity, levonorgestrel provides progestational activity, suppressing gonadotropin (LH and FSH) release from the pituitary, inhibiting ovulation, and altering cervical mucus and endometrial lining to reduce sperm penetration and implantation.
Prempro/Premphase contains conjugated estrogens (CE) and medroxyprogesterone acetate (MPA). Estrogens bind to estrogen receptors (ERα/ERβ), activating genomic and non-genomic signaling, promoting proliferation of estrogen-responsive tissues, and modulating lipid metabolism. MPA is a progestin that binds to progesterone receptors, antagonizing estrogen-induced endometrial hyperplasia and blunting estrogen effects on breast tissue. The combination suppresses gonadotropin secretion via negative feedback on the hypothalamic-pituitary axis.
One tablet containing 0.02-0.05 mg ethinyl estradiol and 0.1-0.15 mg levonorgestrel orally once daily for 21 days, followed by 7 days of placebo or no tablets.
Conjugated estrogens 0.625 mg/medroxyprogesterone acetate 2.5 mg (Prempro) or 0.625 mg/5 mg (Premphase) orally once daily.
None Documented
None Documented
Ethinyl estradiol: 13-27 hours (terminal). Levonorgestrel: 18-30 hours (terminal). Clinical context: steady state achieved in 5-7 days; missed doses may require backup contraception.
Conjugated estrogens: 10-24 hours (terminal, prolonged in hepatic impairment). Medroxyprogesterone acetate: 12-17 hours (terminal).
Urine (40% ethinyl estradiol metabolites, 40% levonorgestrel metabolites); feces (40% ethinyl estradiol, 20% levonorgestrel).
Renal (90-95% as glucuronide and sulfate conjugates; <5% unchanged), biliary/fecal (5-10%).
Category D/X
Category C
Estrogen
Estrogen/Progestin Combination